Histamine H3 receptors regulate vascular permeability changes in the skin of mast cell-deficient mice.
The participation of histamine H(3) receptors in the regulation of skin vascular permeability changes in mast cell-deficient mice was studied. Although intradermal injection of histamine H(3) antagonists, iodophenpropit and clobenpropit, at a dose of 100 nmol/site caused significant increases in skin vascular permeability in both mast cell-deficient (WBB6F1 W/W(v)) and wild-type (WBB6F1 +/+) mice, this response was significantly lower in mast cell-deficient mice than in the wild-type controls. Histamine also caused dose-related increases in skin vascular permeability in both wild-type and mast cell-deficient mice. Significant effects were observed at doses of 10 and 100 nmol/site, and no significant difference in skin vascular permeability was observed between mast cell-deficient and wild-type mice. However, histamine contents of dorsal skin in mast cell-deficient mice were significantly lower than in wild-type mice. In addition, the H(1) antagonists diphenhydramine and chlorpheniramine and the NK(1) antagonists, L-732,138 and L-733,060, were able to antagonize H(3) antagonist-induced skin vascular permeability. These results indicated that blockade of H(3) receptors by H(3) antagonists induce skin vascular permeability through mast cell-dependent mechanisms. In addition, histamine and, to a lesser extent substance P are involved in the reaction.
Hossen
Maria Alejandra
MA
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Okayama University, Tsushima-naka 1-1-1, 700-8530, Okayama, Japan. kamei@phesant.pharm.okayama-u.ac.jp
Fujii
Yoko
Y
Sugimoto
Yukio
Y
Kayasuga
Ryoji
R
Kamei
Chiaki
C
D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects*; D002744:Chlorpheniramine / Q000494:pharmacology; D004155:Diphenhydramine / Q000494:pharmacology; D005070:Evans Blue / Q000494:pharmacology; D005260:Female; D006632:Histamine / Q000032:analysis / Q000494:pharmacology; D017442:Histamine Agonists / Q000494:pharmacology; D006633:Histamine Antagonists / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007271:Injections, Intradermal; D007275:Injections, Intravenous; D007550:Isothiuronium / Q000031:analogs & derivatives* / Q000494:pharmacology; D008407:Mast Cells / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008817:Mice, Mutant Strains; D010880:Piperidines / Q000494:pharmacology; D018100:Receptors, Histamine H3 / Q000502:physiology*; D012867:Skin / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D013890:Thiourea / Q000031:analogs & derivatives* / Q000494:pharmacology; D014364:Tryptophan / Q000031:analogs & derivatives* / Q000494:pharmacology
D017442:Histamine Agonists; D006633:Histamine Antagonists; D007093:Imidazoles; D010880:Piperidines; D018100:Receptors, Histamine H3; C086089:3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan; C103788:3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine; C085755:4-(1H-imidazol-4-ylmethyl)piperidine; D007550:Isothiuronium; C077791:iodophenpropit; D002744:Chlorpheniramine; D005070:Evans Blue; D006632:Histamine; D014364:Tryptophan; D004155:Diphenhydramine; D013890:Thiourea; C086108:clobenpropit